Metabolism & Elimination The metabolic fate of KLOW Blend involves parallel processing of four distinct peptides [20]: BPC-157: Plasma half-life under 30 minutes but biological effects persist for hours to days TB-500: Estimated 2-3 hour half-life with C-terminal degradation patterns GHK-Cu: Estimated 2-4 hour half-life involving copper release and peptide fragmentation KPV: Estimated 1-2 hour half-life with rapid peptidase degradation to amino acids Complex interactions between components may influence individual clearance rates All components metabolize to amino acids that enter normal metabolic pathways A significant pharmacokinetic paradox exists across all components: despite rapid plasma clearance (30 minutes to 4 hours), biological effects often persist well beyond plasma elimination, suggesting tissue retention, active metabolite formation, persistent signaling cascade activation, or gene expression changes that outlast peptide presence
Shen, J., Yang, X., Dong, A., Petters, R
Research & Evidence Current evidence for 5-Amino-1MQ centers on preclinical (animal and cell) research on NNMT inhibition, with limited human data to date
Benefits: BPC-157 is commonly used to repair tendons, ligaments, muscles, ulcers, & organ damage
Month 3: The Relief Phase (Weeks 9-12) Most patients experience dramatic improvement during month 3
